Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda

Executive Summary

The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.

You may also be interested in...



If You Build It, Will They Come? Vital That UK MHRA Creates Right Environment For Medtechs

The Medicines and Medical Devices Act presses the UK to regulate in such a way that makes the market attractive for industry and investment. Medtech manufacturers insist the MHRA must strike the right balance as it brings its ‘plan for a new agency’ to life, said the ABHI’s Phil Brown, in the second of a two-part industry view of UK medtech’s regulatory future.

UK Device Safety To Be Enhanced By Patient Safety Commissioner

Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.

UK All-Party Report Assesses Brexit Medtech Impact While Germany Worries Over Border Delays

Government and industry in the UK are determined to make the best of the Brexit free trade deal, but German medtechs are eager for trade flow practicalities to be prioritized.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT142401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel